Why Biotech Stocks Move After FDA Regulatory Green Lights
Biotech stocks often move sharply following regulatory green lights because approval events fundamentally alter a company’s risk profile, revenue visibility, and strategic positioning. In the US market, where the FDA serves as the primary gatekeeper for commercialization, a single regulatory decision can redefine valuation assumptions almost overnight. Key Point Details Regulatory De-risking FDA approvals remove … Read more